Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 18/20 | 0.59 |
| ▸ | DRD3 | P35462 | 18/20 | 0.59 |
| ▸ | HTR1D | P28221 | 2/20 | 0.52 |
| ▸ | HTR1B | P28222 | 2/20 | 0.52 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.43 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.42 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7974488 | 0.94 | DRD2 (0.60) | DRD2DRD3HTR1DHTR1BHDAC1 | |
| SCHEMBL7846244 | 0.88 | DRD2 (0.75) | DRD2DRD3HTR1DHTR1B | |
| SCHEMBL7976525 | 0.85 | DRD2 (0.79) | DRD2DRD3HTR1DHTR1BHDAC1 | |
| SCHEMBL7976527 | 0.85 | DRD2 (0.79) | DRD2DRD3HTR1DHTR1BHDAC1 | |
| SCHEMBL7962830 | 0.84 | DRD3 (0.61) | DRD2DRD3HTR1DHTR1BHDAC1 | |
| SCHEMBL7962861 | 0.84 | DRD2 (0.77) | DRD2DRD3HTR1DHTR1BHDAC1 | |
| SCHEMBL7962862 | 0.84 | DRD2 (0.77) | DRD2DRD3HTR1DHTR1BHDAC1 | |
| SCHEMBL7846242 | 0.83 | DRD2 (0.77) | DRD2DRD3HTR1DHTR1B | |
| SCHEMBL7853339 | 0.81 | DRD2 (0.65) | DRD2DRD3HTR1DHTR1B | |
| SCHEMBL7853775 | 0.81 | DRD2 (0.82) | DRD2DRD3HTR1DHTR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6274593-B1 | TREATING PSYCHOLOGICAL DISORDERS, SCHIZOPHRENIA, AND PARKINSON*S DISEASE | SMITHKLINE BEECHAM P.L.C. (GB) | 2001-08-14 | — | — | US | claimed |
| EP-0980357-A1 | SUBSTITUTED TETRAHYDRO ISOQUINOLINES AS MODULATORS OF DOPAMINE D3 RECEPTORS | SMITHKLINE BEECHAM PLC (GB) | 2000-02-23 | — | — | EP | claimed |
| WO-1998050363-A1 | SUBSTITUTED TETRAHYDRO ISOQUINOLINES AS MODULATORS OF DOPAMINE D3 RECEPTORS | SMITHKLINE BEECHAM PLC (GB) | 1998-11-12 | — | — | WO | claimed |
| US-6274593-B1 | TREATING PSYCHOLOGICAL DISORDERS, SCHIZOPHRENIA, AND PARKINSON*S DISEASE | SMITHKLINE BEECHAM P.L.C. (GB) | 2001-08-14 | — | — | US | disclosed |
| EP-0980357-A1 | SUBSTITUTED TETRAHYDRO ISOQUINOLINES AS MODULATORS OF DOPAMINE D3 RECEPTORS | SMITHKLINE BEECHAM PLC (GB) | 2000-02-23 | — | — | EP | disclosed |
| WO-1998050363-A1 | SUBSTITUTED TETRAHYDRO ISOQUINOLINES AS MODULATORS OF DOPAMINE D3 RECEPTORS | SMITHKLINE BEECHAM PLC (GB) | 1998-11-12 | — | — | WO | disclosed |